Identifying genetic variants influencing human brain structures may reveal new biological mechanisms underlying cognition and neuropsychiatric illness. The volume of the hippocampus is a biomarker of incipient Alzheimer's disease 1,2 and is reduced in schizophrenia 3 , major depression 4 and mesial temporal lobe epilepsy 5 . Whereas many brain imaging phenotypes are highly heritable 6, 7 , identifying and replicating genetic influences has been difficult, as small effects and the high costs of magnetic resonance imaging (MRI) have led to underpowered studies. Here we report genome-wide association meta-analyses and replication for mean bilateral hippocampal, total brain and intracranial volumes from a large multinational consortium. The intergenic variant rs7294919 was associated with hippocampal volume (12q24.22; N = 21,151; P = 6.70 × 10 −16 ) and the expression levels of the positional candidate gene TESC in brain tissue. Additionally, rs10784502, located within HMGA2, was associated with intracranial volume (12q14.3; N = 15,782; P = 1.12 × 10 −12 ). We also identified a suggestive association with total brain volume at rs10494373 within DDR2 (1q23.3; N = 6,500; P = 5.81 × 10 −7 ).
The hippocampal formation is a key brain structure for learning, memory 8, 9 and stress regulation 10 and is implicated in many neuro psychiatric disorders. Further, overall brain and head sizes are altered in many disorders and are significantly correlated with general cogni tive ability [11] [12] [13] . Hippocampal, total brain and intracranial volumes are highly heritable in nonhuman primates 14, 15 and in humans 6, 7 . Finding loci that influence these measures may lead to the identifica tion of genes underlying susceptibility for neuropsychiatric diseases. Here we sought to identify common genetic polymorphisms influ encing hippocampal, total brain and intracranial volumes in a large multinational consortium.
Our discovery sample comprised 17 cohorts of European ancestry from whom genomewide SNPs and structural MRI data were collected (Supplementary Tables 1-3 ). Unselected population samples and casecontrol studies were included, with cases ascertained for neuro psychiatric disorders including depression, anxiety, Alzheimer's dis ease and schizophrenia. To distinguish whether putative effects at these loci varied with disease status, analyses were run in the full sample (N = 7,795) and in a healthy subsample (N = 5,775). To help disentangle overall brain size effects from those specific to hippocampal volume, associations were assessed with and without controlling for total brain and intracranial volumes (Online Methods). As the initial goal of the study was to explore associations with hippocampal volume, total brain and intracranial volumes were analyzed in healthy subjects only.
Phenotypes were computed from threedimensional anatomical T 1 weighted magnetic resonance images, using validated auto mated segmentation programs [16] [17] [18] ( Supplementary Fig. 1 and Supplementary Tables 4 and 5). Extensive quality control analysis of segmentation was performed on sample outliers; subjects with poorly delineated brain volume phenotypes were removed ( Supplementary  Figs. 2-6 ). The mean bilateral hippocampal volume across the dis covery cohorts was 3,917.4 mm 3 (s.d. = 441.0 mm 3 ).
Heritability of structural brain phenotypes was estimated in a sample of Australian monozygotic and dizygotic twins and their siblings (Queensland Twin Imaging (QTIM) study; N = 646, including ungenotyped participants; age range = 20-30 years) for hippocampal volume (h 2 = 0.62), total brain volume (h 2 = 0.89) and intracranial volume (h 2 = 0.78). Hippocampal volume was also highly heritable in an extended pedigree cohort of MexicanAmericans from the United States (Genetics of Brain Structure and Function (GOBS); N = 605; age range = 18-85; h 2 = 0.74), as were total brain volume (h 2 = 0.77) and intracranial volume (h 2 = 0.84). All heritability estimates were highly significant (P < 0.001).
To enable consortiumwide comparison of ancestry and to adjust appropriately for population stratification, each site conducted multidimensional scaling (MDS) analyses comparing their data to the HapMap 3 reference populations (Supplementary Fig. 7 ). All subsequent analyses included the following covariates: sex, linear and quadratic effects of age, interactions of sex with age covariates, MDS components and dummy covariates for different magnetic resonance acquisitions. Analyses were filtered for genotyping and imputation quality ( Supplementary Fig. 8 and Supplementary Table 6 ); distributions of test statistics were examined at the cohort level through Manhattan and quantilequantile plots ( Supplementary  Figs. 9-24) . We conducted fixedeffects metaanalysis with METAL, applying genomic control 19 ( Supplementary Figs. 25-32 ). For com pleteness and to account for heterogeneity across sites, a random effects metaanalysis was also performed 20 ( Supplementary  Figs. 33-40) . We attempted in silico replication of the top five loci for each trait within the combined CHARGE Consortium discovery set and 3C replication sample 21 (N = 10,779), as well as in two cohorts of European ancestry (imputed to the Utah residents of Northern and Western European ancestry (CEU) and/or Toscani in Italy (TSI) HapMap cohorts; N = 449) and in two additional cohorts (imputed to combined CEU and Yoruba in Ibadan, Nigeria (YRI), and to Mexican ancestry in Los Angeles, California (MEX); N = 842). We also undertook custom genotyping of the two most promising SNPs in two additional samples of European ancestry (BIG replication and Trinity College Dublin/National University of Ireland, Galway (TCD/NUIG); N = 1,286).
In general, previously identified poly morphisms associated with hippocampal volume showed little association in our meta analysis (BDNF, TOMM40, CLU, PICALM,  ZNF804A, COMT, DISC1, NRG1, DTNBP1;  Supplementary Table 7) , nor did SNPs pre viously associated with schizophrenia 22 and bipolar disorder 23 (Supplementary Table 8 ).
The most significant SNPs in each analysis from the discovery sample (P ≤ 5 × 10 −5 ) are listed (Supplementary Tables 9-16 ). No markers reached genomewide significance (P < 1.25 × 10 −8 ; Online Methods) in the dis covery sample alone. However, the strongest associations for hippocampal and intracranial volumes were replicated, yielding results at genomewide significance ( Fig. 1 and Table 1; see Supplementary Tables 17-25 for additional  results and genebased tests 24 ) .
In our discovery sample, two SNPs in the same linkage disequilib rium (LD) block showed strong associations with hippocampal volume after controlling for intracranial volume (rs7294919 and rs7315280; r 2 = 0.81, CEU 1000 Genomes Pilot 1). A randomeffects analysis of the discovery sample, conducted to examine heterogeneity between cohorts, reduced significance only slightly for rs7294919 (P = 4.43 × 10 −7 ) compared to the primary fixedeffects analysis (P = 2.42 × 10 −7 ). The association was consistent, although stronger, in the full sample compared to the healthy subset (Fig. 2) . Notably, the association was robust to the effects of head and brain size (Fig. 2) , and the locus was not significantly associated with intracranial volume (P = 0.54) or total brain volume (P = 0.41). This suggests an effect at the level of the hippocampus rather than on brain size in general. The direction of the effect was consistent across samples and ages (Fig. 1) . Haplotype analysis of directly genotyped variants near rs7294919 in two samples confirmed that the association was present across the haplotype and that the causal variant was well marked by rs7294919 (Supplementary Note). rs7294919 was also significantly associated with hippocampal volume in the cohorts from the CHARGE Consortium, which are composed of elderly subjects. Metaanalysis of the Enhancing Neuro Imaging Genetics through MetaAnalysis (ENIGMA) discovery and replication samples with those from the CHARGE Consortium yielded a highly significant association for rs7294919 (P = 6.70 × 10 −16 ; N = 21,151).
rs7294919 lies between HRK and FBXW8 (12q24.22; Fig. 1 ) and is not in LD with any SNPs within coding sequences, UTRs or splice sites within 500 kb (r 2 > 0.4) in the CEU sample from the 1000 Genomes Project Phase 1. To determine whether the observed association is related to a regulatory mechanism, we examined poten tial cis effects of this variant on expression levels of genes within a 1Mb region. In temporal lobe tissue resected from 71 individuals with mesial temporal lobe epilepsy and hippocampal sclerosis in the University College London (UCL) epilepsy cohort, we examined association between rs4767492 (a proxy for rs7294919, which was not directly genotyped; r 2 = 0.636 in 1000 Genomes Project Phase 1) and expression levels. This analysis suggested an association (P = 0.006, controlling for age) with expression of the TESC gene, which lies 3′ to FBXW8 (149 kb; Fig. 3 ). To corroborate this finding, we used the publicly available SNPExpress database (see URLs), which includes data on gene expression in postmortem frontal cortex from 93 subjects. In this independent sample, expression levels of TESC Figure 1 Association results and meta-analysis of effects in individual and combined analyses. (a) The strongest association with hippocampal volume was found for rs7294919. Fixedeffects meta-analysis P values are shown 41 after controlling for intracranial volume using all subjects in the discovery sample. (b) The strongest association with intracranial volume was found for rs10784502. Fixed-effects metaanalysis P values are shown in healthy subjects only. (c,d) The effect within each sample contributing to the meta-analysis is shown in forest plots for hippocampal volume (c) and intracranial volume (d). Association data using intracranial volume as a phenotype were not available for the EPIGEN sample. Head size was not controlled for in the CHARGE Consortium association analyses. l e t t e r s npg l e t t e r s again significantly differed by genotype (rs4767492; P = 0.0021). Additional replication came from the UK Brain Expression Database, where TESC expression in postmortem brain tissues from 134 indivi duals free from neurological disorders showed a strong difference by genotype in temporal cortex (rs7294919; P = 9.7 × 10 −4 for gene and 4.8 × 10 −5 for exon 8). Given the small sample sizes and low minor allele frequency of this SNP (MAF = 0.099), no homozygotes for the minor allele were observed in any brain tissue sample, limiting the inferences we can draw regarding mode of action. Expression of HRK showed little evidence of association with the proxy genotype in the UCL epilepsy cohort (P = 0.11) or SNPExpress (P = 0.16) but was associated with rs7294919 in temporal cortex within the UK Brain Expression Database (P = 0.0051). Additional associations were observed in peripheral blood mononuclear cells (PBMCs; Supplementary Note).
The expression results in brain tissue suggest that TESC is a primary positional candidate for our quantitative trait locus (QTL). Studies of mouse and chicken embryos show that TESC is expressed throughout the brain during development, with the strongest expression in the devel oping telencephalon and mesencephalon and near the developing ven tricles 25 . TESC also has moderate expression in the human hippocampus during adulthood (Allen Institute Brain Atlas, see URLs; Fig. 3 ). Its pro tein product, tescalcin, interacts with the Na + /H + exchanger (NHE1) 26 , which is involved in the regulation of intracellular pH 21 , cell volume and cytoskeletal organization 27 . TESC expression is strongly regulated during cell differentiation in a cell lineage-specific fashion 28, 29 . Our data suggest that this role in cell proliferation and differentiation is relevant for hippocampal volume and brain development. npg l e t t e r s
The strongest association with intracranial volume was observed at rs10784502 ( Table 1) , an intronic SNP near the 3′ UTR of the HMGA2 gene (12q14.3; Fig. 1 ). This locus was associated with intracranial volume across lifespan, as shown by the strong replication in samples from healthy elderly individuals in the CHARGE Consortium. The combined analysis resulted in the identification of a highly significant association (P = 1.12 × 10 −12 ). Of note, rs10784502 has been reliably associated with increased adult height (P = 3.636 × 10 −32 ; effect allele: C) 30 . The genetic correlation between height and intracranial volume within the QTIM sample was significant (r g = 0.31; P = 1.34 × 10 −7 ), as was that observed in the GOBS sample (r g = 0.20; P = 0.026), suggest ing modest overlap of shared genetic determinants. rs10784502 also had an effect on total brain volume in the discovery sample (P = 9.49 × 10 −5 ). When considering the results from the intracranial volume meta analysis in SNPs previously associated with height [31] [32] [33] (N SNPs = 175; Supplementary Fig. 41 ), a clear inflation of the test statistic was observed (λ = 1.44), indicating that SNPs associated with height are also associated with intracranial volume. This enrichment, which was not observed for hippocampal volume ( Supplementary  Figs. 42 and 43) , was due to a systematically higher degree of association throughout the candidate SNP set rather than a small number of large effects. Structural equation modeling showed that the effect of rs10784502 on intracranial volume could not completely be accounted for by the indirect effects of this SNP on height or by the correlation between height and intracranial volume (Supplementary Fig. 44 ).
Examining correlations between rs10784502 and expression levels of genes within a 1Mb region, we identified a significant effect on the expression of HMGA2 (P = 0.0077) as the single significant result in the GOBS transcriptional profile data. Additionally, HMGA2 expression levels in PBMCs were significantly negatively genetically Figure 3 Regulatory effects of hippocampal-associated variant and expression of TESC within the hippocampus. (a-d) The locus most associated with hippocampal volume was also associated with mRNA expression of the TESC gene in brain in three independent samples, the UCL epilepsy cohort (a), the SNPExpress database (b), where a proxy SNP was used, and the UK Brain Expression Database (d), where differences in TESC expression of the directly genotyped hippocampal variant (rs7294919) were strongest in the temporal cortex (TCTX) (red box) but also found in the average expression of all cortex (AvgCTX) and average expression of all brain structures tested (AvgALL). Symbol color represents genotype in a and d. These regional gradients in expression support the hypothesis that the SNP may associate with hippocampal but not total brain volume. No effects were detected in PBMCs from the SNPExpress database (c). CRBL, cerebellar cortex; FCTX, frontal cortex; HIPP, hippocampus; MEDU, medulla (specifically the inferior olivary nucleus); OCTX, occipital cortex; PUTM, putamen; SNIG, substantia nigra; THAL, thalamus; WHMT, intralobular white matter. (e) TESC is differentially expressed within the fetal human brain (P = 1.33 × 10 −12 ), with the highest expression in striatum (STRIAT) and hippocampus (HIPP) 42 . Box plots represent median and 25th to 75th percentiles. Upper and lower lines show minimum and maximum values, respectively. CBLM, cerebellum; DLPFC, dorsolateral prefrontal neocortex; MPFC, medial prefrontal neocortex; MS, motor-somatosensory neocortex; OCC, occipital visual neocortex; OFC, orbital prefrontal neocortex; PAS, parietal association neocortex; TAC, temporal association neocortex; TAU, temporal auditory neocortex; THAL, mediodorsal thalamus; VLPFC, ventrolateral prefrontal neocortex. (f) TESC has moderate to high gene expression throughout the adult human hippocampus (shown in green), as visualized in the Allen Institute Human Brain Atlas using Brain Explorer 2 software. An inferior view of the brain is shown in two subjects; the anterior portion of the brain is at the top. The colors of spheres within the hippocampus indicate the Z-scores of TESC expression normalized within each subject across brain structures. Heat maps show that expression of TESC is higher in the hippocampus (HiF) and striatum (Str) than in other brain structures.
npg l e t t e r s correlated with intracranial volume (r g = −0.49; P = 0.016) in this cohort. These results support HMGA2 as a positional candidate gene underlying our observed QTL. HMGA2 encodes the highmobility group AThook 2 protein, which is a chromatinassociated protein that regulates stem cell renewal during development 34 . It is implicated in human growth through genetic association studies and the pres ence of rare mutations 35 and also has known roles in neural precursor cells 36 . Whether both functions are due to the same underlying mech anisms warrants further study. To test for pleiotropic effects of rs7294919 and rs10784502, we examined the influence of these variants on cognition in the Brisbane Adolescent Twin Study 37 (N = 1642) . The C allele of rs10784502, which was associated with increased intracranial volume, was also associated with increased fullscale IQ, as measured via the Multidimensional Aptitude Battery 38 (effect size (β) = 1.29, standard error (S.E.) = 0.47; P = 0.0073; phenotypic correlations are shown in Supplementary  Table 26 ). This effect was driven by performance (PIQ; β = 1.74, S.E. = 0.61; P = 0.0044) rather than by verbal subtests (VIQ; P = 0.103). rs7294919 was not associated with fullscale IQ (P = 0.139) or PIQ (P = 0.489) but showed nominal association with VIQ (effect allele: C; β = 0.126, S.E. = 0.062; P = 0.043).
No associations at genomewide significance were detected for total brain volume. Following inclusion of the replication samples, the strongest evidence for association was detected at rs10494373 within DDR2 (1q23.3; P = 5.81 × 10 −7 ) ( Table 1) , which encodes a receptor tyrosine kinase involved in cell growth and differentiation 39 .
The current study identified and replicated two quantitative trait loci for hippocampal and intracranial volumes across lifespan in a large sample including both healthy subjects and those with neuro psychiatric diagnoses. The rs7294919 variant was associated with decreased hippocampal volume of 47.6 mm 3 or 1.2% of the average hippocampal volume per risk allele. Although further work is neces sary to confirm the causal variant(s) and functional mechanisms, this QTL influencing hippocampal volume differences may act by regulat ing expression of TESC specifically within the brain. In addition, the C allele of rs10784502 is associated, on average, with 9,006.7 mm 3 larger intracranial volume, or 0.58% of intracranial volume per risk allele and is weakly associated with increased general intelligence by approximately 1.29 IQ points per allele.
It has previously been hypothesized that brain imaging endo phenotypes would have large effect sizes; however, this has proven not to be the case for the specific volumetric traits measured here, which had comparable effect sizes to those observed in other genomewide asso ciation studies of complex traits 40 . Notably, the discovery sample had 99.92% power to detect variants with effect sizes of 1% of the variance for MAF ≥ 0.05. It remains to be determined whether specific genetic variations linked to volumetric brain differences are also associated with other neuropsychiatric disorders, brain function and other cognitive traits. If this is the case, neuroimaging genetics may also discover new treatment targets related to the neurobiology of these disorders, in addi tion to improving phenomenologically based diagnostic criteria. Imaging at the University of California, Los Angeles. This research was also supported by NIH grants (P30 AG010129 and K01 AG030514) and by the Dana Foundation. ADNI was launched in 2003 by the NIA, the NIBIB, the FDA, private pharmaceutical companies and nonprofit organizations as a 5year public private partnership. The primary goal of ADNI has been to test whether serial MRI), positron emission tomography (PET), other biological markers and clinical and neuropsychological assessments can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease. Determination of sensitive and specific markers of very early Alzheimer's disease progression is intended to aid researchers and clinicians in developing new treatments and monitoring their effectiveness, as well as lessening the time and cost of clinical trials. The Principal Investigator of this initiative is M.W. Weiner. ADNI is the result of efforts of many coinvestigators from a broad range of academic institutions and private corporations, and subjects have been recruited from over 50 sites across the United States and Canada. The initial goal of ADNI was to recruit 800 adults ages 55 to 90 to participate in the research-approximately 200 cognitively normal older individuals to be followed for 3 years, 400 people with MCI to be followed for 3 years and 200 people with early Alzheimer's disease to be followed for 2 years. For uptodate information, please visit the ADNI website (see URLs). 
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oNLINe MeTHods
All participants provided written informed consent, and studies were approved by the respective Local Research Ethics committees or Institutional Review Boards. MRI scans came from previously collected data. Suggested protocols for imaging analysis are publicly available on the ENIGMA Consortium web site (see URLs); however, any validated segmentation software was permitted. Accuracy of segmentation programs is influenced by scanner and headcoil type and scanner sequences and by participant characteristics, such as age. Each site was permitted to use any validated automated segmentation algorithm that worked most accurately in their data set. The two most commonly used hippo campal segmentation packages were the FMRIB's Integrated Registration and Segmentation Tool (FIRST) 16 from the FMRIB Software Library (FSL) package of tools 43 and FreeSurfer 17 . Brain volume, the sum of gray and white matter excluding ventricles and cerebrospinal fluid (CSF), was calculated using the FSL FMRIB's Automated Segmentation Tool (FAST) 44 package or FreeSurfer. Estimated total intracranial volume was calculated through registration of each MRI scan to a standard brain image template 18 , using either FSL FLIRT 45 or FreeSurfer (exceptions referenced in Supplementary Table 2 ). To calculate intracranial volume, the inverse of the determinant of the transformation matrix was multiplied by the template volume (1,948,105 mm 3 ). Extensive quality control analysis on phenotype segmentations included manual exami nation of phenotype volume histograms (Supplementary Figs. 2-6 ) and box plots of all volumetric measures. Outliers were manually evaluated by over laying the automated segmentations on the original MRI scan. Subjects were excluded from the analysis if structures were poorly segmented.
As assessed previously, the correlation in volumes between automatic and manually segmented hippocampi was high; the accuracy was reported to be higher with FreeSurfer than with FIRST in one study (FreeSurfer r = 0.82; FIRST r = 0.66) 46 and similar between the two in another (FreeSurfer r = 0.73; FIRST r = 0.71) 47 . Scanrescan reliability was also high for both methods (FreeSurfer intraclass correlation (ICC) = 0.98; FIRST ICC = 0.93) 48 . We undertook a largescale assessment to determine the correspondence between segmentations from both FSL and FreeSurfer in the same subjects. Correspondence was found to be reasonably high for average bilateral hippo campal segmentation (r = 0.75; N = 6,093; Supplementary Table 4) . This is close to the agreement between different human raters, as quantified by inter rater reliability (ICC = 0.73-0.85) 49, 50 , which may be a reasonable upper bound on the accuracy of automated segmentation. Brain volume and intracranial volume were delineated with high correspondence between the two methods (r = 0.95, r = 0.90, respectively; N = 4,321).
Heritability estimates for trait measures were calculated in two familybased samples, QTIM and GOBS. Estimates for the QTIM sample used a twin and sibling analysis within Mx. An extended family analysis in Sequential Oligogenic Linkage Analysis Routines (SOLAR) 51 was used for the GOBS sample.
Given sample size and the heritability of hippocampal volume, power calcu lations were performed using the Genetic Power Calculator 52 . We had 99.92% power to detect variants with effect sizes of 1% of the variance and 71.16% power to detect variants with effect sizes of 0.5% of the variance for MAF ≥ 0.05.
All cohorts were genotyped using commercially available arrays. Genetics protocols were developed to standardize the filtering, imputation and asso ciation of genomewide genotype data (see ENIGMA protocols in URLs). SNPs were filtered out of samples on the basis of standard quality control criteria, including low MAF (<0.01), poor genotype calling (call rate of <95%) and deviations from HardyWeinberg equilibrium indicating possible errors in genotyping (P < 1 × 10 −6 ). Genotyping methods and exceptions to these thresholds are summarized in Supplementary Table 3 .
Genetic homogeneity within each sample was assessed through MDS plots (Supplementary Fig. 7) . Ancestry outliers were excluded through visual inspection. A standardized population template from HapMap 3 represent ing those sampled was selected for imputation. Performance of software for imputation is generally similar between the most used methods 53, 54 for com mon variants (MACH 55 , IMPUTE 56 and BEAGLE 57 ); the protocols provided included use of the MACH tool. As raw genotype data were not directly trans ferred to the metaanalysis site, a histogram of allele frequency differences between each contributing group and the HapMap 3 CEU population was gen erated for each group (Supplementary Fig. 8 ) to further examine genotyping and imputation quality. A simulation to determine the effect of varying quality control thresholds on imputation quality (Supplementary Table 6) showed that the minor variation in quality control thresholds and imputation reference panels between sites was unlikely to have influenced imputation accuracy.
Genomewide association analyses were performed that included and excluded individuals with disease. Including individuals with disease (all subjects) offers advantages of greater sample size and wider phenotype dis tribution, which may provide greater power to detect genetic effects [58] [59] [60] . We reanalyzed phenotypes after we excluded individuals with disease to confirm that the observed associations were not due to confounds relating to disease, medication or the possibly altered environments and experiences of these persons. To aid in the interpretation of results, we reanalyzed hippocampal volume after controlling for intracranial volume and total brain volume in two separate analyses. This helped to determine whether the observed associations were caused by direct effects on hippocampal volume or were attributable to more global associations with head size. In addition, genomewide asso ciation analyses of intracranial volume and brain volume were conducted in the healthy controls to clarify whether observed associations were specific to hippocampal volume or influenced brain size in general. Participating sites were asked to conduct five genomewide association analyses (three analyses of hippocampal volume, intracranial volume and brain volume). In addi tion, cohorts with groups of individuals with disease were asked to perform hippocampal analyses including data from these individuals.
Evidence for association was assessed using the allelic dosage of each SNP (accounting for familial relationships in the GOBS, QTIM and SYS samples). SNPderived covariates were tested as fixed effects, while explicitly modeling the genetic relationships between family members in these pedigreebased studies 51, 61, 62 . Analyses used multiple linear regression with the phenotype of interest as a dependent variable and the additive dosage of each SNP as an independent variable of interest, controlling for covariates of population strati fication (four MDS components), age, age 2 , sex and the interactions between age and sex and age 2 and sex. Dummy covariates were used to control for dif ferent scanner sequences or equipment within a site when needed. We refer to these covariates as 'other covariates' , and these were included in all analyses. The extensive regression model was used to statistically control for factors known to affect hippocampal volume that are not specific genetic influences. Recommended protocols for association were provided to the studies based on those used in mach2qtl software (see ENIGMA protocols).
To combine information from multiple studies, we generated a secure web accessible upload site for participants to upload their association results. An automated system parsed the uploaded results files (see URLs). This parser was designed to read raw results files from a variety of association software packages (mach2qtl, PLINK, SOLAR, SNPTEST, QUICKTEST, Merlinoffline and ProbABEL), perform a series of tests on the incoming data to ensure quality, correctly assign the effect allele (dependent on both the imputation and association programs used) and correctly scale the β values and standard errors from association into the same units. Quality control was performed on imputed SNPs to filter out SNPs with low frequency (MAF of <0.01) or poor imputation quality (estimated R 2 of <0.3). Result files and summary statistics from each group were pooled for metaanalysis. Metaanalysis was undertaken for each SNP across all groups based on a fixedeffects model using an inverse standard error-weighted metaanalysis protocol implemented in METAL 19 . Genomic control was applied at the level of each study and at the metaanalysis level to adjust for population stratification or cryptic relatedness not accounted for by MDS components 63 . To account for heterogeneity across samples, a randomeffects metaanalysis 20 was also conducted via the pro gram METASOFT without using genomic control. Using KGG 64 we performed genebased tests on the double genome-controlled metaanalysis results, using the extended Simes test 24 to obtain an overall P value for association of the entire gene with a 50kb boundary on either side. Results from genes with P ≤ 1 × 10 −4 are presented (Supplementary Tables 18-25) .
Metaanalysis was performed separately on the discovery sample, the CEU and TSI replication sample and the CEU and YRI or MEX replication sample. These results were then pooled to form the combined metaanalysis statistics for discovery and replication. The in silico replication results from the CHARGE Consortium were added to this, and a final metaanalysis was conducted. The location of Manhattan and quantilequantile plots is specified in Supplementary Table 27. npg To appropriately account for the multiple comparisons conducted, we first sought to determine the effective number of independent phenotypes among the eight highly correlated genomewide association analyses. This was cal culated by creating an 8 × 8 matrix derived from crosscorrelations of meta analytic t statistics of association for each SNP across phenotypes. The result ing correlation matrix provided an estimate of the similarity between pheno types after adjusting for covariates of interest and appropriately controlling for family structure. The effective number of tests was then calculated by summing eigenvalues of the correlation matrix, weighted by a formula that appropriately controls false positive rates in simulation 65 . The effective number of tests was determined to be 4 and an overall genomewide significance threshold of 5 × 10 −8 /4 = 1.25 × 10 −8 was used throughout the manuscript.
Regulatory potential of SNPs identified in the genomewide association analysis was examined in three samples. In the UCL epilepsy cohort, tissue was obtained from resection material from affected individuals who had undergone surgery for drugresistant mesial temporal lobe epilepsy with hippocampal sclerosis, according to established clinical protocols. Total RNA from the middle temporal cortex (Brodmann areas 20 and 21) from 86 sub jects was isolated and randomly hybridized to Affymetrix Human Exon 1.0 ST arrays, and quality control analysis was performed using standard meth ods. The effects of several methodological (day of expression hybridization, RNA integrity number (RIN)) and biological covariates (sex, age and medica tion) on exon-gene expression relationships were tested for significance. Of these individuals, 71 had participated in a published epilepsy genomewide association study, and, therefore, genotyping data were available. Details of sample collection and genotyping quality control steps have been published previously 66 . These samples were assayed with Illumina HumanHap550v3 (N = 44) and Illumina Human610Quadv1 (N = 27) arrays.
In the UK Brain Expression database, postmortem brain tissues from 134 individuals free from neurological disorders were obtained from the MRC Sudden Death Brain Bank in Edinburgh and Sun Health Research Institute 67 . Genotype information was obtained using Illumina HumanOmni 1M arrays and standard quality control methods. Expression profiling was conducted in up to ten separate brain regions for each individual brain using the Affymetrix GeneChip Human Exon 1.0 ST array. Expression levels were normalized using the Robust Multiarray Analysis (RMA) algorithm restricting to probe sets containing more than three probes, unique hybridization target (probes that map to a single position within the genome) and supported by evidence from EntrezGene. The average signals for all neocortex (AvgCTX) and all brain regions (AvgAll) were tested, as were individual cortical and subcortical regions. Any significant association where the probe set contained the SNP or a SNP in high LD (r 2 > 0.50) was removed from further analysis.
SNPExpress, a publically available database, was also used for replication of the findings. The SNPExpress database 68 used autopsycollected frontal cortex brain tissue in 93 samples from human subjects with no neuropsychiatric con ditions and PBMCs in 80 samples. In this database, transcript expression levels were measured on Affymetrix Human ST 1.0 exon arrays, and genomewide genotyping was performed using Illumina HumanHap550K arrays.
Raw gene expression data from human fetal brain were gathered from a published study 42 . Postmortem specimens from four late midfetal human brains (18, 19, 21 and 23 weeks of gestation) were collected from the Human Fetal Tissue Repository at the Albert Einstein College of Medicine. Details of specimens, tissue processing, microdissection and neuropathological assessment have been described elsewhere 42 .
